An observational study in Necrotizing Pancreatitis, sponsored by Chunling Jiang. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-10.
Sponsored by Chunling Jiang · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Pancreatitis, Acute Necrotizing with a site in China — 6 open to participants now, 6 under way, none of them phase 3. Pancreatitis, Acute Necrotizing · China.
Among the 17 studies in Pancreatitis, Acute Necrotizing with a site in China, this one is the only one that started in 2024, is one of 3 observational ones, and was the 14th registered.
75 studies on the registry are indexed under Pancreatitis, Acute Necrotizing; 20 are open to participants now.
Browse Pancreatitis, Acute Necrotizing studies →6 of the 17 studies in Pancreatitis, Acute Necrotizing with a site in China are open now. Recruiting first, the newest first:
Zhejiang University · Sites in China
Ages 18–75
First People's Hospital of Hangzhou · Sites in China
Ages 18+
West China Hospital · Sites in China
Ages 18+
Almazov National Medical Research Centre · Sites in China, Russia
Ages 18+
The First Affiliated Hospital of Nanchang University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 12 Pancreatitis, Acute Necrotizing studies recruiting now, 9 (75%) set no upper age limit and 3 (25%) stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 101 across 26 observational studies indexed under Pancreatitis, Acute Necrotizing.
Median enrollment 135 across the 14 interventional studies, 200 across the 3 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 17 has an industry lead sponsor. The 10 most frequent:
Chunling Jiang is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Chunling Jiang has 1 study filed under Pancreatitis, Acute Necrotizing — fewer than ten, so there is no comparison to draw.
4 of the studies in Pancreatitis, Acute Necrotizing with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07093996Almazov National Medical Research CentreEndoscopic Pancreatic Duct Stent Placement Versus Conventional Approach in the Treatment of Early Phase Acute Pancreatitis | 2026-12-01 |
| NCT07201246West China HospitalOrgan Dysfunction Changes in Acute Necrotizing Pancreatitis Patients With Sepsis Following Open Necrosectomy | 2026-12-30 |
| NCT06380842Chunling JiangOrgan Dysfunction Change in Acute Necrotizing Pancreatitis Patients With Sepsis After Open Necrosectomy | 2026-12-30 |
| NCT07080697Zhejiang UniversityA Study to Evaluate Splenectomy on Debridement for Acute Necrotizing Pancreatitis With Pancreatic Sinistral Portal Hypertension | 2027-02-28 |
Add all 4 to your calendar (.ics) → With an account.
Among the 17 studies in Pancreatitis, Acute Necrotizing with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to characterize organ dysfunction change in acute necrotizing pancreatitis patients with sepsis after open necrosectomy.
Before surgery, study participants will be asked questions about age, gender, education level, etc. Study participants will also be questioned regarding pancreatic symptoms, as measured on the Patient-Reported Outcome Scale in Acute Pancreatitis (including pain, abdominal distention, eating, bowel movements, nausea and vomiting, thirst, and weakness). Organ dysfunction was defined according to the Sequential Organ Failure Assessment (SOFA) score. The SOFA score will be measured at preoperative (T1), postoperative day 1 (T2), postoperative day 3 (T3), postoperative day 7, or at hospital discharge, whichever comes first (T4). Participants who provide optional consent for biospecimen collection will have peripheral venous blood samples (5-10 mL) collected at predefined preoperative and postoperative time points. Samples will be processed and stored for biomarker analyses, including inflammatory marker measurement, metabolomic profiling, and other exploratory analyses related to the objectives of this study. Following discharge from the hospital, study participants will be contacted at 1 month, 3 months, 6 months, and 1 year after surgery, and asked to complete a survey about their pancreatic symptoms and survival status after surgery.
Acute necrotizing pancreatitis Patients with sepsis scheduled for open necrosectomy will be invited to participate in this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Acute necrotizing pancreatitis patients with sepsis undergoing open necrosectomy will be measured SOFA scores at a special time point to characterize organ dysfunction experience profiles.
Other: Necrotizing Pancreatitis patients' organ dysfunction progression
Study the dynamic nature of organ dysfunction
Measure organ dysfunction change after open necrosectomy with respect to time
Organ dysfunction will be measured using sequential organ failure assessment score scale. The scores range from 0 (normal) to 4(most abnormal) for each organ, with higher scores indicating worse health status
Time frame: up to postoperative day 7, or at hospital discharge, whichever comes first
incidence of a composite of major complications
Major complications were defined as new-onset organ failure (ie, cardiovascular, pulmonary, or renal)
Time frame: up to postoperative day 28
Incidence of ICU mortality
Death occurred in ICU
Time frame: through study completion, an average of 1year
Incidence of hospital mortality
Death occurred in hospital
Time frame: through study completion, an average of 1 year
Incidence of 28-day mortality
Death occurred within 28-day after surgery
Time frame: through study completion, an average of 1 year
Incidence of one year mortality
Death occurred within one year after surgery
Time frame: through study completion, an average of 1 year
ICU length of hospital stay
Determined by the number of days from ICU admittance to discharge from ICU
Time frame: through study completion, an average of 1 year
Length of hospital stay
Determined by the number of days from admittance to discharge
Time frame: through study completion,an average of 1 year
The pancreatic symptoms score
Pancreatic symptom scores will be measured at preoperative, postoperative day 1, day 2, day 3, day 7, or at hospital discharge, whichever comes first, at 1 month, 3 months, 6 months, and 1 year postoperatively. Both were measured using the Patient-Reported Outcome Scale, which ranges from 0 to 10 for each symptom; The overall range is from 0 to 70, with higher scores indicating higher symptom intensity.
Time frame: up to 1 year
The levels of inflammatory factor CRP
Peripheral blood CRP
Time frame: preoperative, postoperative day 1, day 3 and day 7 or at hospital discharge, whichever came first.
The levels of inflammatory cytokines IL-6
cytokines IL-6
Time frame: preoperative, postoperative day 1, day 3 and day 7 or at hospital discharge, whichever came first.
The levels of inflammatory procalcitonin
procalcitonin was measured at preoperative, postoperative day 1, day 3 and day 7 or at hospital discharge, whichever came first.
Time frame: preoperative, postoperative day 1, day 3 and day 7 or at hospital discharge, whichever came first.
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2024 (actual). Primary completion is estimated for Dec 2026, 30 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pancreatitis, Acute Necrotizing →
Chunling Jiang